{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'The Death eCRF is provided immediately after the occurrence or outcome of death is', 'reported. Initial and follow-up reports regarding death must be completed within one', 'week of when the death is reported.', '8.3.6.', 'Disease-Related Events and/or Disease-Related Outcomes Not', 'Qualifying as SAEs', 'The events or outcomes listed in the CDC Classification System for HIV-1 Infections', '(Section 11.12) will be recorded on the HIV-Associated Conditions eCRF page if they', 'occur. However, these individual events or outcomes, as well as any sign, symptom,', 'diagnosis, illness, and/or clinical laboratory abnormality that can be linked to any of these', 'events or outcomes are not reported to ViiV/GSK as AEs and SAEs even though such', 'event or outcome may meet the definition of an AE or SAE, unless the following', 'conditions apply:', 'The investigator determines that the event or outcome qualifies as an SAE under part', '\"f\" of the SAE definition (see Section 11.8), or', \"The event or outcome is in the investigator's opinion of greater intensity, frequency\", 'or duration than expected for the individual participant, or', 'Death occurring for any reason during a study, including death due to a', 'disease-related event, will always be reported promptly.', 'Lymphomas and invasive cervical carcinomas are excluded from this exemption; they', 'must be reported as SAEs even if they are considered to be HIV-related.', '8.4.', 'Treatment of Overdose', 'For this open-label study, any tablet intake exceeding the randomized daily number of', 'tablets for DTG/3TC FDC will be considered an overdose [Dolutegravir (TIVICAY)', 'Product Insert, 2017; EPIVIR Product Information, 2017]. ViiV Healthcare does not', 'recommend specific treatment for an overdose of DTG/3TC FDC. As appropriate, the', 'Investigator should use clinical judgment and also refer to the prescribing information for', 'the individual drugs used for CAR in treating overdose in the CAR arm.', 'For the purposes of this study, an overdose is not an AE unless it is accompanied by a', 'clinical manifestation associated with the overdose. If the clinical manifestation presents', 'with serious criteria, the event is a SAE (see Section 11.8). If an overdose occurs and is', 'associated with an adverse event requiring action, all study medications should be', 'temporarily discontinued until the adverse event resolves.', 'In the event of an overdose, the investigator or treating physician should:', 'Contact the Medical Monitor immediately.', 'Closely monitor the participant for AE/SAE and laboratory abnormalities until', 'DTG/3TC FDC can no longer be detected systemically (at least 2 days).', 'Obtain a plasma sample for PK analysis within 60 hours from the date of the last dose', 'of study intervention if requested by the Medical Monitor (determined on a case-by-', 'case basis).', '65']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Document the quantity of the excess dose as well as the duration of the overdosing in', 'the eCRF.', 'Decisions regarding dose interruptions or modifications will be made by the investigator', 'in consultation with the Medical Monitor based on the clinical evaluation of the', 'participant.', '8.5.', 'Pharmacokinetics', 'Liver Event', 'As part of the follow-up for any liver stopping event, a blood sample for PK analysis will', 'be collected if it can be obtained within 60 hours of the last dose (See Section 11.9.1).', 'Overdose', 'Only if requested by the Medical Monitor, as part of the follow-up for any suspected', 'overdose, a blood sample for PK analysis will be collected if it can be obtained within 60', 'hours from the date of the last dose of study intervention (See Section 8.4).', '8.6.', 'Pharmacodynamics', 'Pharmacodynamic parameters are not evaluated in this study.', '8.7.', 'Genetics', 'Genetics are not evaluated in this study.', '8.8.', 'Biomarkers', 'Blood and urine are being collected to perform renal, bone and inflammatory biomarker', 'assessments.', 'Renal biomarkers:', 'Cystatin C (blood)', 'Retinol Binding Protein (RBP, urine),', 'Beta-2-Microglobulin (B2M, urine)', 'Urine RBP/creatinine ratio', 'Urine B2M/creatinine ratio', 'urine albumin/creatinine ratio,', 'urine protein/creatinine ratio,', '66']\n\n###\n\n", "completion": "END"}